Synergistic effects of vascular IL-17 and TNFalpha may promote coronary artery disease

Med Hypotheses. 2004;63(4):696-8. doi: 10.1016/j.mehy.2004.03.009.

Abstract

Interleukin (IL)-17 is a pro-inflammatory cytokine originally described in T lymphocytes. Increased production of IL-17 has been linked to the induction of cytokines, chemokines and adhesion molecules in various cell types, effects that likely contribute to a number of inflammatory diseases including rheumatoid arthritis. Importantly, in the same pathophysiological conditions production of TNFalpha is also up-regulated and recent studies suggest that cellular signaling pathways induced by IL-17 and TNFalpha converge. Recent studies showed that vascular endothelial and/or smooth muscle cells also express TNFalpha and IL-17, which can be up-regulated in pro-atherogenic pathophysiological conditions in the coronary arteries. TNFalpha has been shown to exert pro-inflammatory vascular effects (e.g., induction of oxidative stress, endothelial apoptosis, up-regulation of adhesion molecules and chemokines), however, the role of vascular IL-17 and its interaction with TNFalpha is much less understood. We propose that increased vascular IL-17 and TNFalpha levels can act synergistically to create a pro-inflammatory microenvironment promoting the development of atherosclerotic vascular disease.

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Clinical Trials as Topic
  • Coronary Artery Disease / immunology*
  • Coronary Artery Disease / metabolism
  • Evidence-Based Medicine
  • Humans
  • Interleukin-17 / immunology*
  • Interleukin-17 / metabolism
  • Models, Immunological*
  • Tumor Necrosis Factor-alpha / immunology*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Biomarkers
  • Interleukin-17
  • Tumor Necrosis Factor-alpha